Dergiler / Causapedia / 2016 / Cilt: 5 - Sayı: 1

Multipl Sklerozisde Mitoksantron Tedavisiyle İlişkili Akut Promyelositik Lösemi Hematoloji

Acute Promyelocytic Leukemia Associated with Theraphy of Mitoxantrone in Multiple Sclerosis

Sayfa
42–44
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bizlaboratuvar bulgularıyla akut promyelositik lösemisaptadık.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Mitoksantron, relaps ve progresif multiple sklerozistedavisinde kullanılan bir DNA- topoizomerazinhibitörüdür.
📊
Temel Bulgular & Veri:Translokasyon (15,17)pozitif akut promyelosik lösemi mitoksantron kullanankanser hastalarıyla karşılaştırıldırıldığında multiplsklerozislikomplikasyonunmaruziyetle ilişkisi belirsizdir.
💡
Sonuç & Katkı:Bizlaboratuvar bulgularıyla akut promyelositik lösemisaptadık.
🔬Tür:Deneysel Tarla Denemesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Mitoksantron, relaps ve progresif multiple sklerozistedavisinde kullanılan bir DNA- topoizomerazinhibitörüdür. Mitoksantron kullanımı, mitoksantronunkardiyotoksik ve tedavi-ilişkili akut lösemi potansiyelriskleri nedeniyle kısıtlıdır. Translokasyon (15,17)pozitif akut promyelosik lösemi mitoksantron kullanankanser hastalarıyla karşılaştırıldırıldığında multiplsklerozislikomplikasyonunmaruziyetle ilişkisi belirsizdir. Bu nedenle, mitoksantronson dozundan sonraki 5 yıl boyunca hematolojikmonitorizasyon devam etmelidir. Bu çalışmada, biz 20yıldır multipl sklerozis hastası olan bir olguyusunuyoruz. Bu hastada mitoksantron tedavisinin sondozundan 17 ay sonra pansitopeni gelişti. Bizlaboratuvar bulgularıyla akut promyelositik lösemisaptadık. Bu hastaya remisyon indüksiyon ve all-transretinoik asit tedavisi başladık. Hasta pulmoneraspergillozis nedeniyle öldü

Abstract

Mitoxantrone is a DNA-topoisomerase 2 inhibitorused for treatment of relapsing and progressivemultiple sclerosis. Usage of mitoxantrone is limited,because of its potential risk such as cardiotoxicity andthe induction of therapy-related acute leukemia. Acutepromyelocytic leukemia with the translocationt(15;17) was over-represented in the multiple sclerosispopulation in comparison with cancer patients alsotreated with mitoxanrone. The timing of thiscomplication, risk, mortality and relationship toexposure remain uncertain. Therefore, haematologicalmonitoring should continue for at least 5 years afterthe last dose of mitoxantrone. In these report; wepresent a case with multiple sclerosis for 20 years.Pansitopenia developed in these patient after 17months after receive the last dose of mitoxantrone(Cumulative dose:120 mg). We determined acutepromyelocytic leukemia with labaratory finding.Remission induction chemotherapy and all-transretinoic acid was administered to these patient. Shewas died because of pulmonary aspergillosis

🔖

Bu Makaleye Atıf Yap

SİNCAN, G., BİLEN, Y., ERDEM, F., SİNCAN, S. (2016). Multipl Sklerozisde Mitoksantron Tedavisiyle İlişkili Akut Promyelositik Lösemi Hematoloji. Causapedia, Cilt: 5 - Sayı: 1, 42–44. https://ajindex.com/articles/151682

Kaynakça (11)

  1. Tanasescu R, et al. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol. 2004;251:762-763
  2. Pedersen-Bjergaard J, Philip P. Two different classes of therapy related and de novo acute myeloid leukemia?. Cancer Genet Cytogenet. 1991;55:119-124
  3. Pedersen-Bjergaard J, et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76:1083-1091
  4. Ammatuna E, Montesinos P, Hasan SK et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica. 2011; 96(4): 621–625 5. Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004 (28);63:15-18
  5. Marriott JJ, et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463-1470
  6. Rashidi A, Fisher SI. Therapy-related acute promyelocytic leukemia: a systematic review. Med Oncol. 2013; 30(3): 625
  7. Brunning RD, et al. Acute myeloid leukaemias and myelodysplastic syndromes, therapy related. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC press: Lyon; 2001. p. 89–91
  8. Vicari AM, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia. 1998; 12: 441–442
  9. Cattaneo C, et al. A case of acute promyelocytic leukaemia following mitoxantrone treatment of múltiple sclerosis. Leukemia. 2003;17:985-986
  10. Ghalie RG, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler. 2002;8:441-445
  11. Pascual AM, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 2009 Nov;15(11): 1303-1310.